Navigation Links
Accelrys Fast-tracks Scientific Innovation with Modeling and Simulation Software Release
Date:6/20/2012

BRUSSELS, June 20, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio® 3.5 modeling and simulation software during the company's European Science Symposium in Brussels. The latest release extends Discovery Studio's portfolio of small-molecule ligand design and market-leading biological simulation tools, including a new, validated ligand-profiling database for drug repurposing studies, new science to assess the development potential of putative biologics and many additional enhancements that help deliver a highly effective life sciences modeling and simulation environment.

New, validated science built upon active, ongoing partnerships is the keystone underlying the latest Discovery Studio 3.5 release. Discovery Studio's new ligand-profiling solution uses a spatial aggregation propensity algorithm and Developability Index licensed from the Massachusetts Institute of Technology (MIT) and validated in collaboration with Novartis Pharma AG. Capabilities such as these provide important indicators of whether ligands and proteins will be good candidates for downstream development.

"The current economic squeeze on scientific resources across industries is counterbalanced by a continuing critical need for scientific innovation and excellence," said Senior Vice President and Chief Technology Officer Dr. Matt Hahn. "Deploying Discovery Studio modeling and simulation software on the scientifically aware Accelrys Enterprise Platform can help organizations meet the critical performance, cost and innovation goals that define today's increasingly information-driven R&D environments."

Discovery Studio 3.5 accelerates innovative modeling and simulation workflows by providing:

  • New science supporting small-molecule ligand design including a new ligand-profiling database for drug repurposing and side-effect studies; new in situ lead optimization and core-hopping tools for fragment-based drug design; and new activity cliffs and activity effects analysis based on Matched Molecular Pairs analysis
  • New science supporting biotherapeutics including new calculations for ranking protein-protein aggregation and improved capability to perform pH-dependent mutation energy (binding) calculations
  • Up-to-date Scientific Collections, enabling organizations to build, deploy, analyze and report on complex scientific data types using the Accelrys Enterprise Platform  
  • Updated partner ecosystem including support for the latest releases of CHARMm molecular simulation software and the MODELER program for comparative protein structure modeling
  • Enhanced usability, accessibility and visualization including enhanced generation of receptor-ligand interaction surfaces and improved display and rendering of 3D molecular objects

Discovery Studio provides comprehensive modeling and simulation capabilities for computational chemists, computational biologists and other scientists engaged in either small or large molecule life sciences R&D. The software speeds innovation, reduces costs, enhances productivity and improves outcomes through the automation and expert use of predictive science.

To learn more about the latest Discovery Studio release, register for the webinar, "What's New in Discovery Studio 3.5," scheduled for Wednesday, June 27.

About Accelrys, Inc.

Accelrys (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

Related Links
Accelrys's Discovery Studio


'/>"/>
SOURCE Accelrys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelrys Announces Software Licensing Agreement with Gulf Coast Consortia
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
4. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
5. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
6. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
7. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
8. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
9. Generex Augments Antigen Express Scientific Advisory Board
10. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
11. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... IRVINE, Calif. , March 24, 2017 ... ,the epigenetics company, and Hamilton Robotics, Inc., ... workstations, announced an ongoing collaboration that teams ... products and RNA and DNA extraction products ... has already created optimized methods for microbiomics ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... offering. ... the worldwide markets for Dental Implants in US$ Million. The report provides ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Drs. Justin ... Awareness Week by teaching their patients about the key role this treatment plays in ... from an experienced endodontist. To better serve those who need a root canal in ...
(Date:3/27/2017)... Scottsdale, Arizona (PRWEB) , ... March 27, 2017 , ... ... in the top 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo ... New York on April 8. , Project Entrepreneur’s second annual venture competition ignites ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... ... 27, 2017 , ... The Association of Healthcare and Value ... their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide the ... value analysis professionals have a ‘seat at the table’ with clinical committees when ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announce the launch of a months-long rebranding effort. This includes the introduction of ... focus group discussions and market research, we learned that a simple, proactive approach ...
Breaking Medicine News(10 mins):